Reid G. Adler Net Worth

The estimated Net Worth of Reid G. Adler is at least $1.05 Million dollars as of 17 August 2022. Reid Adler owns over 300,000 units of Vistagen Therapeutics stock worth over $1,054,081 and over the last 3 years Reid sold VTGN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Reid Adler VTGN stock SEC Form 4 insiders trading

Reid has made over 1 trades of the Vistagen Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Reid bought 300,000 units of VTGN stock worth $51,000 on 17 August 2022.

The largest trade Reid's ever made was buying 300,000 units of Vistagen Therapeutics stock on 17 August 2022 worth over $51,000. On average, Reid trades about 50,000 units every 0 days since 2022. As of 17 August 2022 Reid still owns at least 334,629 units of Vistagen Therapeutics stock.

You can see the complete history of Reid Adler stock trades at the bottom of the page.

What's Reid Adler's mailing address?

Reid's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Vistagen Therapeutics

Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore, and Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.

What does Vistagen Therapeutics do?

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Complete history of Reid Adler stock trades at Vistagen Therapeutics

Vistagen Therapeutics executives and stock owners

Vistagen Therapeutics executives and other stock owners filed with the SEC include:

• Shawn Singh,
  Chief Executive Officer, Director
• Shawn K. Singh J.D.,
  CEO & Director
• H. Ralph Snodgrass,
  President, Founder, Chief Scientific Officer, Director
• Jerrold Dotson,
  Chief Financial Officer, Vice President, Secretary
• Mark Smith,
  Chief Medical Officer
• Dr. Mark A. Smith M.D., Ph.D.,
  Chief Medical Officer
• Dr. H. Ralph Snodgrass Ph.D.,
  Founder, Pres & Chief Scientific Officer
• Jerrold D. Dotson CPA, CPA,
  CFO, VP & Sec.
• Mark McPartland,
  Vice President - Corporate Development
• Jon Saxe,
  Independent Chairman of the Board
• Ann Michelle Cunningham M.B.A.,
  Chief Commercial Officer & Director
• Valter Pinto,
  Investor Relations
• Brian Underdown,
  Independent Director
• Jerry Gin,
  Independent Director
• Ann Cunningham,
  Independent Director
• Dr. Mark J. Ginski,
  Sr. VP and Head of Chemistry, Manufacturing & Controls
• Mark Adrian McPartland,
  VP of Corp. Devel.
• Healthcare Capital Partners...,
  
• Margaret M Fitz Patrick,
  
• Joanne Curley,
  
• Mary L. Rotunno,
  
• Mark J Ginski,
  SENIOR VP, HEAD OF CMC
• Joshua S. Prince,
  Chief Operating Officer
• Cynthia Lynn Anderson,
  CHIEF FINANCIAL OFFICER
• Capital Lp Commodore,
  10% owner
• Reid G. Adler,
  CHF CORP DEVEL OFF, GEN COUNS